Sugar 8.65% in 7 days Crane producers -14.79% in 15 days Coal Producers -30.93% in 27 days Silver -21.18% in 60 days Home improvers sector 24.61% in 3 months Network services providers 39.1% in 4 months Injectable Drugs Manufacturers -45.66% in 9 months Railcar and transportation stock prices 166.45% in 18 months insurance annuity annuities 161.17% in 3 years Latin America -80.99% in 4 years Uranium -84.77% in 4 years merchants merchant card 212.68% in 4 years Leisure, U.S. 227.72% in 6 years automotive parts repair 492.99% in 6 years Malaysia 293.54% in 14 years Equity, Switzerland 103.2% in 15 years
Latest Strongest Trends:

Drug cell human ublituximab GPCRs Phenoxodiol drugs

Trend Strength: , Change: 6.18% in 29 days

Industries: Biotechnology,Medical Instruments & Supplies,Drug Manufacturers - Other

Top terms: drug cell human ublituximab GPCRs Phenoxodiol drugs pre-clinical discovery proprietary activity Pracinostat orphan receptors intellectual compounds GPCR Novogen pharmaceutical proteins agents repurchase CLL death disorders signaling Cadus Vulcan lead Protein-coupled function GECS postoperative rituximab exclusive demonstrated issue screenin

Trending Motif Instruments Open in screener...

Trend will be:

Continued - 0%No opinion - 100%Reversed - 0%

Horizon

Healthcare

Symbol Name Type Description
PKI PerkinElmer Inc S&P500 PKI, PerkinElmer, Inc. provides technology, services, and solutions to the diagnostics, research, environmental and safety, and industrial and laboratory services markets worldwide.
PKI

Relevant?

MEIP MEI Pharma, Inc. Stock MEI Pharma, Inc., a development-stage oncology company, focuses on the clinical development of therapeutics for the treatment of cancer. Its lead drug candidate is Pracinostat, an orally available histone deacetylase inhibitor, which is in Phase II clinical trial for the treatment of hematologic diseases, such as myelodysplastic syndrome and acute myeloid leukemia. The company's clinical development pipeline also includes two isoflavone-based drug candidates comprising ME-143, a NADH oxidase inhibitor drug candidate that is in Phase II clinical trial for the treatment of ovarian cancer; ME-344, an anti-cancer agent, which is in Phase I clinical trial for the treatment of cancer; and PWT143, which is in pre-clinical development for the treatment of cancer. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was founded in 2000 and is based in San Diego, California. MEI Pharma, Inc. is a subsidiary of Novogen Li
MEIP

Relevant?

OMER Omeros Corporation Stock Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes products targeting inflammation, coagulopathies, and disorders of the central nervous system. Its clinical products include Omidria, which has completed two Phase III clinical trials for use during intraocular lens replacement, including cataract and other lens replacement surgery; OMS103 that is in Phase III clinical program for use during arthroscopic procedures, such as partial meniscectomy surgery; and OMS824, which is in Phase II clinical trial for the treatment of CNS disorders comprising schizophrenia and Huntington's disease. Its clinical programs also consist of OMS721 that is in Phase II clinical trial for the treatment of various complement-related diseases and disorders, including thrombotic microangiopathies; OMS405, which is in Phase II clinical trial for the treatment and prevention of addiction to substances of abuse; and OMS201 that has completed Phase 1/Phase 2 clin
OMER

Relevant?

TGTX TG Therapeutics, Inc. Stock TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of various pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The company is developing two therapies targeting hematological malignancies. Its therapies include TG-1101, a chimeric glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency. The company is based in New York, New York.
TGTX

Relevant?

Trending Motif News

Sort by:   Time / Relevance

 

2014-06-03 21:40:04

yahoo sector-healthcare

Omeros' Omidria Gets FDA Nod

2014-06-03 14:19:00

businesswire

Research and Markets: Brain Cancer Drug Pathway Analyzer 2014

2014-06-03 14:10:00

businesswire

Research and Markets: Ovarian Cancer Drug Pathway Analyzer 2014 - 320 targeted molecular therapies known to affect more than 250 pathways

2014-06-03 14:03:00

businesswire

Research and Markets: Leukemia Drug Pathway Analyzer Report 2014: 379 targeted molecular therapies known to affect more than 244 pathways

2014-06-03 14:00:00

businesswire

Research and Markets: Renal Cancer Drug Pathway Analyzer 2014 - 221 Targeted Molecular Therapies

2014-06-03 12:48:00

businesswire

Research and Markets: Mitochondrial Drugs in Oncology Drug Pipeline Update 2014 - 240 companies plus partners developing 259 mitochondrial drugs

2014-06-03 12:05:00

businesswire

Research and Markets: VEGF Signaling Pathway in Cancer Drug Pipeline Update 2014

2014-06-03 12:01:00

businesswire

Research and Markets: Targeting Natural Killer Cell Mediated Cytotoxicity in Cancer Drug Pipeline Update 2014

2014-06-02 11:00:00

prnewswire

Omeros Receives FDA Approval of Omidriaâ„¢ for Use in Cataract and Other Intraocular Lens Replacement Procedures

2014-05-30 15:17:00

businesswire

Research and Markets: ErbB Signaling Pathway in Cancer Drug Pipeline 2014: 222 companies plus partners developing 356 ErbB signaling pathway targeting drugs in 1304 developmental projects

2014-05-30 15:04:00

businesswire

Research and Markets: MAPK Signaling Pathway in Oncology Drug Pipeline 2014: 229 companies plus partners developing 319 MAPK signaling pathway targeting drugs in 1195 developmental projects

2014-05-30 14:49:00

businesswire

Research and Markets: Fc Epsilon RI Signaling Pathway in Oncology Drug Pipeline 2014 - 124 companies plus partners developing 178 Fc epsilon RI signaling pathway targeting drugs

2014-05-30 14:13:00

businesswire

Research and Markets: TSLP Signaling Pathway in Oncology Drug Pipeline Analysis 2014: 181 Companies Plus Partners Developing 257 TSLP Pathway Targeting Drugs in 936 Developmental Projects

2014-05-27 11:00:00

prnewswire

Novogen Identifies Highly Active Drug Candidates Against Prostate Cancer

2014-05-27 11:00:00

businesswire

Trevena CEO to Present at the Jefferies 2014 Global Healthcare Conference

2014-05-23 21:28:00

businesswire

Research and Markets: Selective JAK Inhibitors for Rheumatoid Arthritis

2014-05-23 08:31:00

businesswire

Research and Markets: Global Neuropathic Pain Report 2014: Daiichi Sankyo's DS5565 - Forecast and Market Analysis to 2022

2014-05-15 12:07:00

businesswire

Research and Markets: IL-3 Signaling Pathway in Oncology Drug Pipeline Update 2014

2014-05-15 11:37:00

businesswire

Research and Markets: IL-2 Signaling Pathway in Oncology Drug Pipeline Update 2014

2014-05-15 08:00:00

prnewswire

Heptares to Present at UBS Global Healthcare Conference and Upcoming Scientific Events

2014-05-13 14:01:00

prnewswire

JAK and PI3K Signaling Pathway Markets

2014-05-13 10:10:00

businesswire

Research and Markets: Global IL-9 Signaling Pathway in Oncology Drug Pipeline 2014: 61 Companies Plus Partners Developing 64 IL-9 Pathway Targeting Drugs in 251 Developmental Projects

2014-05-13 10:09:00

businesswire

Research and Markets: TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline 2014: 288 Companies Plus Partners Developing 403 TGF-Beta Receptor Pathway Targeting Drugs in 1356 Developmental Projects

2014-05-13 09:06:00

businesswire

Research and Markets: IL-5 Signaling Pathway in Oncology Drug Pipeline Report 2014 - Jump start competitive drug intelligence operations

2014-05-13 08:58:00

businesswire

Research and Markets: IL-1 Signaling Pathway in Oncology Drug Pipeline Update 2014

2014-05-09 12:30:00

globenewswire

TG Therapeutics, Inc. to Host Conference Call on First Quarter 2014 Financial Results and Business Update

2014-05-08 23:48:00

businesswire

Research and Markets: TSH Signaling Pathway in Oncology Drug Pipeline Update 2014

2014-05-08 23:29:00

businesswire

Research and Markets: FSH Signaling Pathway in Oncology Drug Pipeline Update 2014

2014-05-08 22:03:00

businesswire

Research and Markets: TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update 2014

2014-05-08 20:21:00

businesswire

Research and Markets: Global Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014

2014-05-08 20:12:00

businesswire

Research and Markets: EGFR1 Signaling Pathway in Oncology Drug Pipeline Update 2014

2014-05-08 20:08:00

businesswire

Research and Markets: B Cell Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014

2014-05-08 19:38:00

businesswire

Research and Markets: Alpha6 Beta4 Integrin Signaling Pathway in Oncology Drug Pipeline Update 2014

2014-05-02 11:15:00

businesswire

Trevena to Host Conference Call on May 9th to Discuss First Quarter 2014 Financial Results and Recent Highlights

2014-04-29 15:14:00

prnewswire

Cell Analysis Market by Instruments, Consumables & Application- Global Forecast to 2018

2014-04-28 17:46:00

businesswire

Research and Markets: Global Cell Analysis Market 2014-2019: Instruments (Flow Cytometer, Microscope, Microfluidics, QPCR) & Application (Cell ID, Cell Viability, Cell Proliferation, Cytology, Signal Transduction, Single Cell)

2014-04-23 13:09:00

businesswire

Research and Markets: Invega for Schizophrenia Treatment - Global Forecast and Market Analysis to 2022

2014-04-15 10:05:00

businesswire

Research and Markets: Global Fanapt (Schizophrenia) - Forecast and Market Analysis to 2022

2014-04-07 12:30:00

globenewswire

TG Therapeutics, Inc. Announces Preclinical Poster Presentations for TGR-1202 at AACR 2014

2014-04-07 11:00:00

prnewswire

Omeros to Present at the 13th Annual Needham Healthcare Conference

2014-04-03 11:00:00

prnewswire

Investigational New Drug Application Cleared by FDA for OMS721 in Thrombotic Microangiopathies

2014-04-01 20:01:00

businesswire

Trevena CEO to Present at the 13th Annual Needham Healthcare Conference

2014-03-27 23:27:54

globenewswire

Five Prime Therapeutics Announces Upcoming Presentations at the 2014 American Association for Cancer Research Meeting

2014-03-27 14:13:55

ap

Daughter: Berezovsky thought he had been poisoned

2014-03-27 13:45:00

marketwire

DiscoveRx and Collaborators Present Data on Safety, Bioactivities of Wide Range of Substances to Society of Toxicology

2014-03-21 11:00:00

prnewswire

Omeros to Present at BioCentury Future Leaders in the Biotech Industry Conference

2014-03-19 21:19:00

prnewswire

Omeros Closes $40.25 Million Public Offering of Common Stock

2014-03-14 12:33:00

prnewswire

Omeros Prices $35.0 Million Public Offering of Common Stock

2014-03-13 20:37:05

yahoo sector-healthcare

Omeros Announces Proposed Public Offering of Common Stock

2014-03-13 20:36:00

prnewswire

Omeros Announces Proposed Public Offering of Common Stock

2014-03-13 20:16:00

prnewswire

Omeros Corporation Reports Fourth Quarter and Year-End 2013 Financial Results

2014-03-13 20:16:00

businesswire

Trevena to Host Conference Call on March 20th to Discuss Full Year 2013 Financial Results and Recent Highlights

2014-03-12 15:00:00

prnewswire

Novogen to Present at 2nd Annual Sachs Cancer Bio Partnering & Investment Forum in New York

2014-03-10 21:50:05

zacks

Additional Positive Data on Omeros Treatment

2014-03-07 11:15:00

prnewswire

Heptares to Present at Upcoming Biotech Business Development Events

2014-03-06 12:00:00

prnewswire

Omeros Reports Additional Positive Data from its OMS824 Phase 2a Schizophrenia Clinical Trial

2014-03-05 13:52:00

prnewswire

Omeros Closes $32 Million Debt Financing, Receiving $12.6 Million in New Funds

2014-03-05 12:00:00

businesswire

Trevena CEO to Present at the Barclays Global Healthcare Conference

2014-02-28 13:33:00

prnewswire

MEI Pharma Receives Orphan Status For Lead Drug Candidate Pracinostat For Treatment Of Acute Myeloid Leukemia

2014-02-26 12:00:00

prnewswire

Omeros to Present at Cowen and Company 34th Annual Health Care Conference

2014-02-20 22:00:05

yahoo sector-healthcare

Omeros Doses First Patient in a Study

2014-02-19 12:00:00

prnewswire

Omeros Announces Enrollment in Second Phase 2 Clinical Trial with OMS824

2014-02-14 20:30:04

yahoo sector-healthcare

Additional Data on Omeros' OMS824

2014-02-12 12:36:48

flyonthewall

Regado Biosciences announecs USPTO issues new patent to company

2014-02-07 21:00:00

globenewswire

TG Therapeutics, Inc. to Present at the 16th Annual BIO CEO & Investor Conference

2014-02-07 13:42:00

prnewswire

OMS Corporation Launches As a Spin-off Company of MetroLaser's Vibrometer Business

2014-01-29 12:00:00

prnewswire

Omeros Reports Positive Results from OMS824 Phase 2a Clinical Trial

2014-01-23 09:00:00

prnewswire

Heptares Successfully Completes Research Phase of Antibody Discovery Collaboration with MedImmune

2014-01-20 13:00:00

prnewswire

Reaction Biology and Cisbio Bioassays sign distribution agreement

2014-01-13 21:30:00

globenewswire

TG Therapeutics, Inc. to Present at the 32nd Annual J.P. Morgan Healthcare Conference

2014-01-08 12:30:00

prnewswire

Novogen to Present at Biotech Showcaseâ„¢ 2014

2014-01-03 16:01:00

yahoo category-economy

Google Began The New Year By Continuing Its Brutal Punishment Of Rap Genius

2013-12-20 19:40:00

businesswire

Newman Ferrara LLP Announces Investigation of OSI Systems, Inc.

2013-12-19 15:50:03

zacks

Orphan Drug Designation for Omeros' OMS721

2013-12-18 14:00:00

businesswire

HCA’s Parallon and Sarah Cannon to Relocate to Capitol View

2013-12-18 12:30:00

prnewswire

Domain Therapeutics, Université de Montréal, IRICoR and McGill University sign new licensing and partnership agreement on G-Protein Coupled Receptor biosensor technology

2013-10-17 19:30:04

zacks

Pipeline Progress at Omeros

2013-10-17 11:00:00

prnewswire

Omeros Reports Additional Positive Clinical Data for its Drug Candidate to Treat Cognitive Disorders

2013-10-15 13:59:00

ap

Omeros will study eye surgery drug in children

2013-10-15 11:00:00

prnewswire

FDA Agrees with Omeros' Pediatric Study Plan for OMS302

2013-10-11 09:10:00

businesswire

Research and Markets: Mitochondrial Drugs in Oncology Drug Pipeline Update 2013

2013-10-10 12:30:00

prnewswire

MEI Pharma Announces Topline Data From Phase I Clinical Trial Of Mitochondrial Inhibitor Drug Candidate ME-344

2013-10-10 08:00:00

prnewswire

Heptares Delivers First Stabilised GPCR (StaR®) to MorphoSys for Antibody Discovery

2013-10-08 11:00:00

prnewswire

Omeros Hires Michael K. Inouye to Lead Commercial Operations

2013-10-08 08:00:00

marketwire

Genius Project Version 7.2 Delivers Over 150 Improvements

2013-10-04 21:15:02

yahoo category-legal-matters

Omeros Shares Up on Claim Settlement

2013-10-03 19:58:56

yahoo category-legal-matters

Omeros shares jump on settlement

2013-10-03 12:07:27

yahoo category-legal-matters

Omeros settles insurance litigation with CCIC

2013-10-03 11:00:00

prnewswire

Omeros Unlocks Six Additional Class A Orphan GPCRs and Identifies Small Molecules Targeting Two Commercially Validated Class B GPCRs

2013-10-02 11:00:00

prnewswire

US and European Regulators Accept for Review OMS302 Marketing Applications

2013-09-30 11:00:00

prnewswire

FDA Grants Orphan Drug Designation to Omeros' OMS824 for Huntington's Disease

2013-09-25 12:33:30

flyonthewall

OncoMed granted additional broad anti-RSPO antibody patent in U.S.

2013-09-25 12:30:00

globenewswire

TG Therapeutics, Inc. to Present at BioCentury's NewsMakers in the Biotech Industry Conference

2013-09-20 11:00:00

prnewswire

Omeros Chosen to Present at NewsMakers in the Biotech Industry 2013 Conference

2013-09-19 11:00:00

prnewswire

Omeros Reports Initiation of Phase 2 Clinical Trial with OMS824

2013-09-16 21:54:18

yahoo sector-healthcare

Omeros rises as analyst lifts price target

2013-09-13 17:00:00

wall-street-transcript

Dr. Charles M. Baum, the President and CEO of Mirati Therapeutics, Inc. (MRTX), Interviews with The Wall Street Transcript

2013-09-13 17:00:00

wall-street-transcript

Wall Street Transcript Interview with Dr. Charles M. Baum, the President and CEO of Mirati Therapeutics, Inc. (MRTX)

2013-09-13 15:10:02

yahoo sector-healthcare

New Phase I data on Omeros' OMS824

2013-09-12 11:09:05

flyonthewall

Omeros' OMS824 shows positive Phase 1 results

2013-09-11 20:00:04

zacks

Omeros' OMS302 Filed in the EU

2013-09-10 17:55:00

businesswire

Research and Markets: TSH Signaling Pathway in Oncology Drug Pipeline Update 2013: 163 Companies Plus Partners Are Now Developing 253 TSH Pathway Targeting Drugs in 915 Developmental Projects

2013-09-10 11:00:00

prnewswire

Omeros Submits OMS302 Marketing Authorization Application to European Medicines Agency

2013-09-09 13:04:26

globenewswire

Rhizen Pharmaceuticals S.A Announces a Scientific Presentation on the PI3K-Delta Inhibitor, TGR-1202, at the XV International Workshop on Chronic Lymphocytic Leukemia at Cologne, Germany

2013-09-09 13:00:00

globenewswire

TG Therapeutics, Inc. Announces Pre-Clinical Poster Presentation for TGR-1202 at the 15th International Workshop on Chronic Lymphocytic Leukemia (iwCLL), Cologne, Germany

2013-09-09 11:00:00

prnewswire

Omeros to Present at the Stifel Healthcare Conference 2013

2013-09-09 09:05:00

businesswire

Research and Markets: TGF-Beta Receptor Signaling Pathway in Oncology Drug Pipeline Update 2013

2013-09-09 09:03:00

businesswire

Research and Markets: TSLP Signaling Pathway in Oncology Drug Pipeline Update 2013

2013-09-06 11:20:00

businesswire

Research and Markets: Epigenetic Therapy in Oncology Drug Pipeline Update 2013

2013-09-06 10:03:51

globenewswire

Rhizen Pharmaceuticals S.A. announces scientific presentations on the therapeutic potential of their lead dual PI3K delta/gamma inhibitor and CRAC channel inhibitor at the ERS Annual Conference at Barcelona, Spain, 7-11 September 2013

2013-09-06 09:43:00

prnewswire

Heptares to Present at Upcoming Scientific and Biotech Industry Conferences

2013-09-05 13:00:00

prnewswire

MEI Pharma CEO to Present at Stifel Healthcare Conference

2013-08-13 11:00:00

prnewswire

Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer

2013-08-09 20:01:00

prnewswire

Omeros Corporation Reports Second Quarter 2013 Financial Results

2013-08-08 11:00:00

prnewswire

Omeros to Present at the Wedbush 2013 Life Sciences Management Access Conference

2013-08-01 11:00:00

prnewswire

Omeros Submits New Drug Application to U.S. FDA for OMS302

2013-07-31 12:30:00

globenewswire

TG Therapeutics, Inc. to Host Conference Call on Second Quarter 2013 Financial Results and Business Update

2013-07-31 12:03:31

globenewswire

Selexis SA to Present Data on Improved Selection of Recombinant Protein Production Clones at the Bioprocessing Summit 2013

2013-07-30 11:00:00

prnewswire

Mechanism for Cardiac Effects of Trevena Angiotensin Receptor Biased Ligands Examined in Published Study

2013-07-29 11:00:00

businesswire

Acetylon Pharmaceuticals and Celgene Corporation Announce an Exclusive Strategic Collaboration to Advance the Science of Epigenetics

2013-07-22 22:57:00

investors-business-daily

Halliburton tops on int'l work

2013-07-22 07:00:00

prnewswire

Heptares Achieves First Research Milestone in Research Collaboration with Cubist

2013-07-17 17:05:00

prnewswire

Heptares Announces Publication in Nature of Class B GPCR Structure

2013-07-17 15:04:39

ap

Ariad Pharma names Schlesinger as a director

2013-07-17 11:00:00

prnewswire

Trevena Granted Key Composition of Matter Patent for TRV027 in U.S.

2013-07-16 09:35:00

businesswire

Research and Markets: Postoperative Ileus - Pipeline Review, H1 2013

 

Comments

You have to sign in to write a comment.

There is no comments yet.
facebook